Important Information Regarding Vyzulta

Posted in Latest News on March 16, 2018.

During the March 9, 2018 Board of Optometry meeting, the board approved for addition to Rule 64B13-18.002 Formulary of Topical Ocular Pharmaceutical Agents, Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%.

Important note, Vyzulta, at this time, cannot be prescribed by certified Optometrists in Florida until the rule has been approved. Once the rule has gone through the approval process, notice will be provided on this site, and at that time Vyzulta may be prescribed by certified optometrists.

 



More Latest News

Important Notice Regarding Oxervate
January 24, 2020

The Board of Optometry has approved Oxervate (Cenegermin-bkbj) 0.002% for addition to Rule 64B13-18.002. Continue reading


Electronic Prescribing Requirements
January 2, 2020

Click here for the new requirements requiring prescribers to generate and transmit all prescriptions electronically Continue reading